XML 22 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Description of Operations and Summary of Significant Accounting Policies (Details) (USD $)
In Millions, unless otherwise specified
 0 Months Ended 3 Months Ended
Jun. 02, 2014
Jun. 01, 2014
Mar. 31, 2015
Business Separation      
Cash, cash equivalents and marketable securities contributed to Theravance Biopharma   $ 393.0thrx_ContributionOfCashAndCashEquivalentsAndMarketableSecuritiesInBusinessSeparation  
Number of ordinary shares of Theravance Biopharma issued for every share of Theravance 0.286thrx_CommonStockStockDividendRatio    
GSK | LABA collaboration and Strategic Alliance agreements      
Description of operations and summary of significant accounting policies      
Percentage of economic interest in any future payments made under the agreements     15.00%thrx_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
/ us-gaap_CounterpartyNameAxis
= thrx_GSKMember
/ us-gaap_TypeOfArrangementAxis
= thrx_LABACollaborationAndStrategicAllianceAgreementMember